AnorMED Inc., which specializes in the discovery and development of small molecule therapeutics for the treatment of disease, announced in March 24, 2000 that it has received receipts for the issue and sale of 1.5 million special warrants. At a price of $14.00 per special warrant, gross proceeds of the offer total $21 million. The special warrants were sold on a private placement basis through a syndicate led by BMO Nesbitt Burns Inc. and which included RBC Dominion Securities Inc. and CIBC World Markets Inc.
Georald Ingborg and Lata Casciano of Fasken Martineau DuMoulin LLP in Vancouver represented AnorMED, with assistance from Peter Stafford.Hector MacKay-Dunn and Derek Lew of Farris, Vaughan, Wills & Murphy in Vancouver represented the underwriters.
Georald Ingborg and Lata Casciano of Fasken Martineau DuMoulin LLP in Vancouver represented AnorMED, with assistance from Peter Stafford.Hector MacKay-Dunn and Derek Lew of Farris, Vaughan, Wills & Murphy in Vancouver represented the underwriters.
